Arcadia Biosciences, Inc. (RKDA) Form 8-K — Aug 13, 2026
Arcadia Biosciences reported Q2 2026 revenue of $1.443 million, down 1% year over year, with a net loss attributable to common stockholders of $6.3 million, or $2.09 per share, versus a $4.5 million loss a year ago. The wider loss was driven largely by non-cash items, including a $2.8 million unrealized loss on Above Food stock and a $5.4 million valuation loss on the June 2026 PIPE financing. On the balance sheet, Arcadia closed a $4 million private placement in June and ended the quarter with $4.2 million in cash, while net cash used in operating activities was only $319,000 in the quarter and SG&A fell $1.0 million year over year to an all-time low.
Key figures
- Revenue
- 1443000
- Revenue Yoy
- -1%
- Total Assets
- 5893000
- Cash Position
- 4178000
- Shares Outstanding
- 2181715
- H1 2026 revenue usd
- 2543000
- H1 2026 revenue yoy
- -4%
- Q2 2025 revenue usd
- 1455000
- Q2 offering costs usd
- 651000
- Q2 sga decline yoy usd
- 1000000
- July 2026 zola sales usd
- over $740,000
- H1 inducement offer loss usd
- 2877000
- Share count change six months
- +58.9%
- Shares outstanding dec31 2025
- 1373120
- H1 above food unrealized loss usd
- 4300000
- June 2026 pipe gross proceeds usd
- 4000000
- June 2026 pipe valuation loss usd
- 5423000
- Q2 above food unrealized loss usd
- 2800000
- Stockholders equity dec31 2025 usd
- 4140000
- Stockholders equity jun30 2026 usd
- 633000
- Zola sales first week august 2026 usd
- over $1 million
- Warrant option liabilities jun30 2026 usd
- 3614000
- January 2026 inducement offer proceeds usd
- 2082000
Price after filing
Close on the filing date to close N calendar days later (from $0.57). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.